These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20814077)

  • 41. The combination of opioid and neurotensin receptor agonists improves their analgesic/adverse effect ratio.
    Eiselt E; Côté J; Longpré JM; Blais V; Sarret P; Gendron L
    Eur J Pharmacol; 2019 Apr; 848():80-87. PubMed ID: 30707956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of spinal CXCL1 (GROα) in opioid tolerance: a human-to-rodent translational study.
    Lin CP; Kang KH; Lin TH; Wu MY; Liou HC; Chuang WJ; Sun WZ; Fu WM
    Anesthesiology; 2015 Mar; 122(3):666-76. PubMed ID: 25383568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhancing Opiorphin's Metabolic Stability and Preserving its Potent Analgesic Effect: A Systematic Review.
    Tome J; Ibrahim MN; Cowan LT
    Curr Top Med Chem; 2024; 24(1):74-88. PubMed ID: 37933217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.
    Largent-Milnes TM; Yamamoto T; Nair P; Moulton JW; Hruby VJ; Lai J; Porreca F; Vanderah TW
    Br J Pharmacol; 2010 Nov; 161(5):986-1001. PubMed ID: 20977451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity.
    Rougeot C; Messaoudi M; Hermitte V; Rigault AG; Blisnick T; Dugave C; Desor D; Rougeon F
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8549-54. PubMed ID: 12835417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Opiorphin highly improves the specific binding and affinity of MERF and MEGY to rat brain opioid receptors.
    Tóth F; Tóth G; Benyhe S; Rougeot C; Wollemann M
    Regul Pept; 2012 Oct; 178(1-3):71-5. PubMed ID: 22771829
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.
    Largent-Milnes TM; Brookshire SW; Skinner DP; Hanlon KE; Giuvelis D; Yamamoto T; Davis P; Campos CR; Nair P; Deekonda S; Bilsky EJ; Porreca F; Hruby VJ; Vanderah TW
    J Pharmacol Exp Ther; 2013 Oct; 347(1):7-19. PubMed ID: 23860305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of the adjunctive treatment of antidepressants with opiorphin on a panic-like defensive response in rats.
    Maraschin JC; Sestile CC; Yabiku CT; Roncon CM; de Souza Fiaes GC; Graeff FG; Audi EA; Zangrossi H
    Behav Brain Res; 2020 Jan; 378():112263. PubMed ID: 31568834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-activity relationship study of opiorphin, a human dual ectopeptidase inhibitor with antinociceptive properties.
    Rosa M; Arsequell G; Rougeot C; Calle LP; Marcelo F; Pinto M; Centeno NB; Jiménez-Barbero J; Valencia G
    J Med Chem; 2012 Feb; 55(3):1181-8. PubMed ID: 22224710
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacology of peripheral opioid receptors.
    Rachinger-Adam B; Conzen P; Azad SC
    Curr Opin Anaesthesiol; 2011 Aug; 24(4):408-13. PubMed ID: 21659869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analgesia enhancement and prevention of tolerance to morphine: beneficial effects of combined therapy with omega-3 fatty acids.
    Escudero GE; Romañuk CB; Toledo ME; Olivera ME; Manzo RH; Laino CH
    J Pharm Pharmacol; 2015 Sep; 67(9):1251-62. PubMed ID: 26011306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Salivary opiorphin in dental pain: A potential biomarker for dental disease.
    Ozdogan MS; Gungormus M; Ince Yusufoglu S; Ertem SY; Sonmez C; Orhan M
    Arch Oral Biol; 2019 Mar; 99():15-21. PubMed ID: 30590229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of polar side chains modifications on the dual enkephalinase inhibitory activity and conformation of human opiorphin, a pain perception related peptide.
    Rosa M; Marcelo F; Calle LP; Rougeot C; Jiménez-Barbero J; Arsequell G; Valencia G
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5190-3. PubMed ID: 26463133
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term effect of morphine administration in young rats on the analgesic opioid response in adult life.
    Rozisky JR; Dantas G; Adachi LS; Alves VS; Ferreira MB; Sarkis JJ; Torres IL
    Int J Dev Neurosci; 2008 Oct; 26(6):561-5. PubMed ID: 18579332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Injectable liposomal formulations of opiorphin as a new therapeutic strategy in pain management.
    Mennini N; Mura P; Nativi C; Richichi B; Di Cesare Mannelli L; Ghelardini C
    Future Sci OA; 2015 Nov; 1(3):FSO2. PubMed ID: 28031877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of extremely low frequency electromagnetic fields on morphine analgesia and tolerance in rats.
    Ozdemir E; Demirkazik A; Gursoy S; Taskıran AS; Kilinc O; Arslan G
    Gen Physiol Biophys; 2017 Oct; 36(4):415-422. PubMed ID: 28836499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antinociceptive effect induced by a combination of opioid and neurotensin moieties vs. their hybrid peptide [Ile(9)]PK20 in an acute pain treatment in rodents.
    Kleczkowska P; Hermans E; Kosson P; Kowalczyk A; Lesniak A; Pawlik K; Bojnik E; Benyhe S; Nowicka B; Bujalska-Zadrozny M; Misicka A; Lipkowski AW
    Brain Res; 2016 Oct; 1648(Pt A):172-180. PubMed ID: 27473894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120.
    Noble F; Smadja C; Valverde O; Maldonado R; Coric P; Turcaud S; Fournié-Zaluski MC; Roques BP
    Pain; 1997 Dec; 73(3):383-391. PubMed ID: 9469529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Time-course of pain and salivary opiorphin release in response to oral capsaicin differ in burning mouth syndrome patients, temporomandibular disorders patients and control subjects.
    Alajbeg IZ; Vrbanovic E; Alajbeg I; Orabovic I; Naka K; Mrla A; Boucher Y
    Clin Oral Investig; 2024 Apr; 28(5):246. PubMed ID: 38589630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of human opiorphin on food intake and water intake in mice following central administration.
    Chen Y; Tian XZ; Bai L; Liu ZQ; Xiao XP; Liu P; Li XK
    Neurosci Lett; 2017 Feb; 641():62-69. PubMed ID: 28104434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.